Richard Aron Osman

Office of Legal CounselRichard Aron Osman, Ph.D.

Doctor of Laws Chief Legal Counsel, TIMBR/NIBS, Beijing, China

1992    Ph.D. in Judicial Science, University of California, USA

1988    Ph.D. in Molecular Cell Biology University of California, USA

1984    B.S. in Zoology, University of California, USA

2012-    Doctor of Laws Chief Legal Counsel, TIMBR/NIBS, Beijing, China

1995-    Patent Attorney, Science & Technology Law Group, USA

1990-1995    Patent Attorney, USA Flehr, Hohbach, Test, Albritton & Herbert, LLC

The mission of the Legal Department is to advance the programs and operations of NIBS/TIMBR by providing thoughtful, practical, and creative advice, counsel, and other services on legal, policy, and operational matters applicable to NIBS/TIMBR’ programs, operations, and governance. The Legal Department has responsibility for assuring that NIBS/TIMBR receives the legal advice and guidance necessary to assure that its contractual arrangements are appropriate in light of the organization’s activities and objectives and to protect the organization from undue legal and other risk.

Our responsibilities include servicing the intellectual property needs of NIBS/TIMBR and our scientists, including procuring, managing and licensing patents, and facilitating research collaborations and agreements between NIBS/TIMBR and outside scientists and institutions.

-All aspects of patent prosecution, US and International

>500 US patents drafted, filed, prosecuted and issued

>1,000 world-wide patents drafted, filed, prosecuted, issued

>100 appeals before Board of Patent Appeals & Interferences

- Appeals before US Court of Appeals, Federal Circuit

- Interferences before Board of Patent Appeals & Interferences

- Inter Partes and Ex Parte Reexaminations

- Expert opinions re infringement, validity, patentability, FTO

- Contract, negotiations re licensing, ownership, research agreements

In re Berg, 320 F.3d. 1310 (Fed Cir 2003)

In re Ngai, 367 F.3d 1336 (Fed Cir 2004)

Ex parte Jay D. Keasling et al., No. 1997-2755; Ex parte George Chang et al., No. 1997-1770; Ex parte Berg et al., No. 1999-2231; Ex parte Takeshi Sano et al, No. 2000-0630; Ex parte Shervin K. Pishevar, No. 2000-1919; Ex parte Fabienne Charleles De La Brousse et al., No. 2001-1148; Ex Parte Bei Shan et al, No. 2000-0441; Ex parte Gerald M Rubin et al., No. 2004-1106; Ex parte Daniel Tim Curtis et al., No. 2006-1897; Ex parte Steven E. Brenner et al., No. 2006-1569; Ex Parte Joachim Herz et al., No. 2006-2556; Ex parte Richard Harland et al., No. 2007-0079; Ex parte Kevin H. Gardner et al., No. 2007-2956; Ex parte Brett P. Giroir et al., No. 2007-4508; Ex parte Haiying Xia et al., No. 2008-3329; Ex parte Zhigang He et al., No. 2008-6199; Ex parte Wendell Lim et al., No. 2008-3676; Ex parte Duojia Pan et al., No. 2008-6237; Ex parte Deepak Srivastava et al., No. 2008-6034; Ex parte Zhigang He, No. 2008-002333; Ex parte Kevin H. Gardner et al., No. 2009, 009581; Ex parte Srivastava et al., No. 2009-011225; Ex parte Heng Wei Chang, No. 2009-004009; Ex parte Paul R. Selvin et al., No. 2009-013065; Ex parte Richard A. Berg, No. 2010-001516; Ex parte Michael Kyba et al., No. 2010-009979; Ex parte Hani Atamna et al., No. 2011-006151

University of California, Stanford University, Harvard University, University of Texas, University of Illinois, USDA, Children’s Hospital Boston, Children’s Hospital Oakland, SRI International, Amgen, Angiotech, Affymetrix, Exelixis, Incyte, Joyant Pharmaceuticals, Svaya Nanotechnologies

US8172967, US7238659, US7282621, US6399024, US5993457, US7776816, US8013015, US7884211, US7829278, US7065451